Protecting investments in polio eradication: the past, present and future of surveillance for acute flaccid paralysis.
Heymann, DL;
De Gourville, EM;
Aylward, RB;
(2004)
Protecting investments in polio eradication: the past, present and future of surveillance for acute flaccid paralysis.
Epidemiology and infection, 132 (5).
pp. 779-780.
ISSN 0950-2688
DOI: https://doi.org/10.1017/s0950268804002638
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
In September 2003 a WHO consultation group on vaccine-derived polioviruses (VDPV) concluded that in order to prevent future generations of paralytic polio after interruption of transmission of wild poliovirus, the use of trivalent oral polio vaccine (OPV) must be stopped [1]. Another important global policy decision along the road to polio eradication thus became possible – cessation of OPV use at some time after eradication. The question now is not whether OPV must be stopped, but rather when.
